« Back
Home /
PROTAC BCR-ABL Degrader-1

PROTAC BCR-ABL Degrader-1

Item no.	HY-153415-100mg
Manufacturer	MedChem Express
Amount	100 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.09
Formula	C43H40N10O6
Citations	[1]Li C, et al. Proteolysis Targeting Chimeras (PROTACs) Based on Imatinib Induced Degradation of BCR-ABL in K562 Cells. ChemistrySelect, 2023, 8(15): e202300095.
Smiles	CC(C=CC(NC(C1=CC=C(CN2CCN(CC(NC3=CC=CC4=C3C(N(C5C(NC(CC5)=O)=O)C4=O)=O)=O)CC2)C=C1)=O)=C6)=C6NC7=NC=CC(C8=CC=CN=C8)=N7
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Product Description	PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces Bcr-Abl degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
MolecularWeight	792.84
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Pathway	PROTAC; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time